Analyst Reco. Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Market Closed - Nasdaq Other stock markets 04:00:08 2024-05-17 pm EDT			5-day change	1st Jan Change
2.12 ^USD	-1.85%		+11.58%	-36.34%

May. 13	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating	MT
May. 09	Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating	May. 13	MT
HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	Mar. 20	MT
Baird Cuts Coherus BioSciences' Price Target to $9 From $11, Outperform Rating Maintained	Jan. 23	MT
Truist Securities Cuts Coherus BioSciences' Price Target to $8 From $12, Maintains Buy Rating	Jan. 23	MT
Swiss Equities Rally as Rate Decisions, Economic Data Take Center Stage	Jan. 22	MT
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	Dec. 27	DJ
Baird Initiates Coherus BioSciences With Outperform Rating, $11 Price Target	Nov. 17	MT
Maxim Downgrades Coherus BioSciences to Hold From Buy	Nov. 08	MT
HC Wainwright Cuts Price Target on Coherus BioSciences to $13 From $20, Maintains Buy Rating	Nov. 07	MT
Central bank bonanza!	23-10-30
North American Morning Briefing : Rate Decisions, Jobs Data Headline a Busy Week	23-10-30	DJ
Futures jump as investors await Fed rate verdict; Middle East tensions eyed	23-10-30	RE
Barclays Adjusts Coherus BioSciences' Price Target to $7 From $8, Maintains Overweight Rating	23-10-23	MT
UBS Adjusts Coherus BioSciences Price Target to $7 From $11, Maintains Buy Rating	23-08-07	MT
HC Wainwright Adjusts Price Target on Coherus BioSciences to $20 From $24, Maintains Buy Rating	23-08-03	MT
Citigroup Initiates Coherus BioSciences at Buy Rating With $12 Price Target	23-07-24	MT
Truist Securities Trims Price Target on Coherus BioSciences to $20 From $22, Maintains Buy Rating	23-07-14	MT
Truist Securities Trims Price Target on Coherus BioSciences to $22 From $24, Maintains Buy Rating	23-06-20	MT
Barclays Adjusts Coherus BioSciences' Price Target to $8 From $13, Keeps Overweight Rating	23-05-23	MT
HC Wainwright Adjusts Price Target on Coherus BioSciences to $24 From $26, Keeps Buy Rating	23-05-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Analyst Reco.

Filters